Concepts (192)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 36 | 2023 | 2303 | 2.980 |
Why?
|
| Brain | 5 | 2021 | 1346 | 1.440 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2020 | 234 | 1.300 |
Why?
|
| Cerebral Cortex | 5 | 2017 | 290 | 1.230 |
Why?
|
| DNA, Viral | 3 | 2014 | 304 | 1.180 |
Why?
|
| Atrophy | 3 | 2016 | 42 | 1.140 |
Why?
|
| Prefrontal Cortex | 2 | 2018 | 137 | 1.110 |
Why?
|
| Dementia, Vascular | 2 | 2023 | 36 | 1.090 |
Why?
|
| Monocytes | 9 | 2019 | 257 | 1.060 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2021 | 481 | 1.010 |
Why?
|
| AIDS Dementia Complex | 4 | 2021 | 102 | 0.920 |
Why?
|
| Oxidative Phosphorylation | 2 | 2020 | 53 | 0.870 |
Why?
|
| Anti-HIV Agents | 13 | 2021 | 420 | 0.850 |
Why?
|
| Electrocardiography | 2 | 2017 | 156 | 0.710 |
Why?
|
| Heart Rate | 2 | 2017 | 253 | 0.680 |
Why?
|
| Male | 42 | 2023 | 20025 | 0.670 |
Why?
|
| Mitochondria | 2 | 2020 | 487 | 0.670 |
Why?
|
| Alzheimer Disease | 2 | 2023 | 905 | 0.660 |
Why?
|
| Mitochondrial Proteins | 1 | 2019 | 107 | 0.660 |
Why?
|
| Neural Pathways | 1 | 2018 | 124 | 0.610 |
Why?
|
| Middle Aged | 30 | 2021 | 10129 | 0.610 |
Why?
|
| Sympathetic Nervous System | 1 | 2017 | 74 | 0.590 |
Why?
|
| Nerve Net | 1 | 2017 | 76 | 0.570 |
Why?
|
| Cognition Disorders | 5 | 2022 | 233 | 0.550 |
Why?
|
| Deoxyguanosine | 1 | 2016 | 35 | 0.540 |
Why?
|
| Humans | 46 | 2023 | 37093 | 0.540 |
Why?
|
| Viral Load | 6 | 2021 | 312 | 0.520 |
Why?
|
| Cross-Sectional Studies | 13 | 2021 | 2721 | 0.500 |
Why?
|
| Hippocampus | 2 | 2016 | 561 | 0.500 |
Why?
|
| DNA, Mitochondrial | 1 | 2016 | 175 | 0.500 |
Why?
|
| Anti-Retroviral Agents | 6 | 2018 | 147 | 0.490 |
Why?
|
| HIV-1 | 8 | 2020 | 706 | 0.470 |
Why?
|
| Aging | 7 | 2023 | 664 | 0.460 |
Why?
|
| Female | 34 | 2021 | 20969 | 0.450 |
Why?
|
| Cerebellum | 1 | 2013 | 73 | 0.440 |
Why?
|
| Cognition | 7 | 2022 | 398 | 0.430 |
Why?
|
| Depression | 2 | 2018 | 712 | 0.420 |
Why?
|
| Inflammation | 5 | 2018 | 618 | 0.380 |
Why?
|
| Organ Size | 3 | 2020 | 157 | 0.370 |
Why?
|
| Adult | 17 | 2021 | 11712 | 0.360 |
Why?
|
| Longitudinal Studies | 7 | 2023 | 885 | 0.350 |
Why?
|
| Prospective Studies | 6 | 2023 | 1378 | 0.340 |
Why?
|
| Antiretroviral Therapy, Highly Active | 6 | 2023 | 221 | 0.340 |
Why?
|
| Central Nervous System Diseases | 2 | 2019 | 29 | 0.330 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 2 | 2018 | 21 | 0.330 |
Why?
|
| Antigens, CD | 2 | 2018 | 121 | 0.320 |
Why?
|
| Receptors, Cell Surface | 2 | 2018 | 144 | 0.310 |
Why?
|
| Risk Factors | 10 | 2023 | 3562 | 0.300 |
Why?
|
| Thailand | 2 | 2020 | 48 | 0.300 |
Why?
|
| Central Nervous System | 2 | 2018 | 135 | 0.300 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2021 | 189 | 0.290 |
Why?
|
| Cardiovascular Diseases | 3 | 2020 | 664 | 0.270 |
Why?
|
| Hypertension | 2 | 2023 | 796 | 0.270 |
Why?
|
| Insulin Resistance | 2 | 2020 | 184 | 0.260 |
Why?
|
| Aged, 80 and over | 4 | 2023 | 2379 | 0.240 |
Why?
|
| RNA, Viral | 4 | 2020 | 301 | 0.240 |
Why?
|
| Neuropsychological Tests | 5 | 2018 | 259 | 0.240 |
Why?
|
| Longevity | 2 | 2023 | 147 | 0.230 |
Why?
|
| Lipoproteins | 2 | 2014 | 64 | 0.230 |
Why?
|
| Asia | 1 | 2023 | 75 | 0.220 |
Why?
|
| Educational Status | 2 | 2023 | 313 | 0.220 |
Why?
|
| Diabetes Mellitus | 3 | 2020 | 485 | 0.220 |
Why?
|
| Apolipoprotein E2 | 1 | 2022 | 6 | 0.220 |
Why?
|
| Aged | 7 | 2023 | 6741 | 0.210 |
Why?
|
| Vitamin D | 2 | 2016 | 196 | 0.210 |
Why?
|
| Caudate Nucleus | 2 | 2012 | 20 | 0.210 |
Why?
|
| Oxidative Stress | 2 | 2019 | 938 | 0.200 |
Why?
|
| Caenorhabditis elegans | 1 | 2022 | 78 | 0.200 |
Why?
|
| Cerebrovascular Disorders | 2 | 2012 | 37 | 0.200 |
Why?
|
| Receptors, CCR5 | 2 | 2018 | 61 | 0.190 |
Why?
|
| Bone Diseases | 1 | 2020 | 18 | 0.190 |
Why?
|
| Cyclohexanes | 2 | 2023 | 30 | 0.180 |
Why?
|
| Autoantibodies | 1 | 2021 | 103 | 0.180 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2019 | 17 | 0.180 |
Why?
|
| Interferon Regulatory Factors | 1 | 2019 | 17 | 0.180 |
Why?
|
| Electron Transport Complex IV | 1 | 2019 | 37 | 0.180 |
Why?
|
| Myeloid Cells | 1 | 2019 | 29 | 0.170 |
Why?
|
| Stroke | 1 | 2023 | 286 | 0.170 |
Why?
|
| Triazoles | 2 | 2023 | 86 | 0.170 |
Why?
|
| Oxidoreductases | 1 | 2019 | 87 | 0.170 |
Why?
|
| Cohort Studies | 3 | 2019 | 1492 | 0.170 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2021 | 259 | 0.170 |
Why?
|
| Erythrocyte Indices | 1 | 2018 | 13 | 0.170 |
Why?
|
| Benzoxazines | 1 | 2018 | 46 | 0.160 |
Why?
|
| Galectins | 1 | 2018 | 28 | 0.160 |
Why?
|
| Viremia | 1 | 2018 | 42 | 0.160 |
Why?
|
| Receptors, CCR2 | 1 | 2018 | 26 | 0.160 |
Why?
|
| Rest | 1 | 2018 | 26 | 0.160 |
Why?
|
| Erythrocytes | 1 | 2018 | 111 | 0.160 |
Why?
|
| Atherosclerosis | 2 | 2016 | 134 | 0.150 |
Why?
|
| Pilot Projects | 3 | 2018 | 661 | 0.150 |
Why?
|
| Hawaii | 6 | 2022 | 1929 | 0.150 |
Why?
|
| Brain Injuries | 1 | 2018 | 121 | 0.140 |
Why?
|
| Bilirubin | 1 | 2016 | 17 | 0.140 |
Why?
|
| Carotid Artery Diseases | 1 | 2016 | 22 | 0.140 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 357 | 0.130 |
Why?
|
| Serum Amyloid P-Component | 1 | 2015 | 20 | 0.130 |
Why?
|
| Brachial Artery | 1 | 2015 | 28 | 0.130 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2014 | 289 | 0.130 |
Why?
|
| Coronary Vessels | 1 | 2016 | 85 | 0.130 |
Why?
|
| Vasodilation | 1 | 2015 | 65 | 0.130 |
Why?
|
| Young Adult | 3 | 2021 | 4268 | 0.130 |
Why?
|
| Chemokine CCL2 | 1 | 2016 | 85 | 0.130 |
Why?
|
| Ferrosoferric Oxide | 1 | 2013 | 11 | 0.120 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2013 | 12 | 0.120 |
Why?
|
| Polyneuropathies | 1 | 2013 | 10 | 0.120 |
Why?
|
| Reflex | 1 | 2013 | 34 | 0.110 |
Why?
|
| Social Work | 1 | 2013 | 49 | 0.110 |
Why?
|
| DNA Damage | 1 | 2016 | 352 | 0.110 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 461 | 0.110 |
Why?
|
| Niacin | 1 | 2013 | 22 | 0.110 |
Why?
|
| Albuminuria | 1 | 2013 | 76 | 0.110 |
Why?
|
| Calcium | 1 | 2016 | 480 | 0.110 |
Why?
|
| Cytokines | 1 | 2016 | 602 | 0.110 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2014 | 215 | 0.110 |
Why?
|
| Macrophages | 2 | 2013 | 439 | 0.100 |
Why?
|
| Retrospective Studies | 3 | 2016 | 2026 | 0.100 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 105 | 0.100 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2012 | 65 | 0.100 |
Why?
|
| Acne Vulgaris | 1 | 2011 | 7 | 0.100 |
Why?
|
| Cacao | 1 | 2011 | 10 | 0.100 |
Why?
|
| HIV Seropositivity | 1 | 2013 | 190 | 0.100 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2011 | 61 | 0.100 |
Why?
|
| Attention | 1 | 2012 | 156 | 0.100 |
Why?
|
| Pregnancy Complications | 1 | 2012 | 126 | 0.100 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2012 | 162 | 0.090 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2010 | 13 | 0.090 |
Why?
|
| Genotype | 2 | 2023 | 730 | 0.090 |
Why?
|
| Methamphetamine | 1 | 2012 | 159 | 0.090 |
Why?
|
| CD4-CD8 Ratio | 2 | 2020 | 30 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2013 | 854 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2018 | 1130 | 0.080 |
Why?
|
| Lymphocyte Activation | 2 | 2020 | 236 | 0.070 |
Why?
|
| Leukocyte Count | 2 | 2018 | 77 | 0.070 |
Why?
|
| Smoking | 1 | 2012 | 940 | 0.070 |
Why?
|
| Immunophenotyping | 2 | 2016 | 57 | 0.060 |
Why?
|
| Incidence | 2 | 2023 | 922 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 610 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2023 | 19 | 0.060 |
Why?
|
| Phenotype | 2 | 2016 | 689 | 0.060 |
Why?
|
| Age Factors | 2 | 2018 | 1033 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 161 | 0.050 |
Why?
|
| Apolipoprotein E4 | 1 | 2022 | 47 | 0.050 |
Why?
|
| Apolipoproteins E | 1 | 2022 | 129 | 0.050 |
Why?
|
| Alleles | 1 | 2022 | 321 | 0.050 |
Why?
|
| Blood Glucose | 2 | 2014 | 353 | 0.050 |
Why?
|
| Autoantigens | 1 | 2021 | 81 | 0.050 |
Why?
|
| HIV | 1 | 2020 | 98 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 237 | 0.040 |
Why?
|
| Uganda | 1 | 2019 | 22 | 0.040 |
Why?
|
| Neopterin | 1 | 2018 | 13 | 0.040 |
Why?
|
| Cyclopropanes | 1 | 2018 | 40 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2023 | 767 | 0.040 |
Why?
|
| Alkynes | 1 | 2018 | 50 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 186 | 0.040 |
Why?
|
| Macrophage Activation | 1 | 2018 | 56 | 0.040 |
Why?
|
| Calcinosis | 1 | 2016 | 59 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2016 | 159 | 0.030 |
Why?
|
| Receptors, IgG | 1 | 2014 | 50 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 214 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2014 | 46 | 0.030 |
Why?
|
| Disease Management | 1 | 2014 | 61 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2014 | 88 | 0.030 |
Why?
|
| Comorbidity | 1 | 2016 | 623 | 0.030 |
Why?
|
| Prognosis | 1 | 2016 | 739 | 0.030 |
Why?
|
| Zidovudine | 1 | 2013 | 34 | 0.030 |
Why?
|
| Disease Progression | 1 | 2016 | 601 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2013 | 60 | 0.030 |
Why?
|
| Seasons | 1 | 2013 | 112 | 0.030 |
Why?
|
| Occipital Lobe | 1 | 2012 | 5 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2013 | 208 | 0.030 |
Why?
|
| Gyrus Cinguli | 1 | 2012 | 25 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 108 | 0.030 |
Why?
|
| Frontal Lobe | 1 | 2012 | 48 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2012 | 18 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2015 | 484 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2014 | 753 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 400 | 0.020 |
Why?
|
| Gene Expression | 1 | 2014 | 674 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2011 | 53 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 2012 | 136 | 0.020 |
Why?
|
| Marijuana Abuse | 1 | 2012 | 91 | 0.020 |
Why?
|
| Memory | 1 | 2012 | 170 | 0.020 |
Why?
|
| Cell Movement | 1 | 2013 | 571 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 204 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 974 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2013 | 1369 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2012 | 1418 | 0.020 |
Why?
|
| Pregnancy | 1 | 2012 | 1549 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2012 | 583 | 0.020 |
Why?
|
| Animals | 1 | 2022 | 15081 | 0.020 |
Why?
|
| Adolescent | 1 | 2011 | 5363 | 0.010 |
Why?
|